| Id Consultants, P.c. | |
|
1400 Us Highway 61 Ste 260 Festus MO 63028-4101 | |
| (636) 933-2344 | |
| (636) 937-9031 |
| Full Name | Id Consultants, P.c. |
|---|---|
| Speciality | Internal Medicine |
| Location | 1400 Us Highway 61 Ste 260, Festus, Missouri |
| Authorized Official Name and Position | Chandra B. Dommaraju (PRESIDENT) |
| Authorized Official Contact | 6369332344 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Id Consultants, P.c. 1400 Us Highway 61 Ste 260 Festus MO 63028-4101 Ph: (636) 933-2344 | Id Consultants, P.c. 1400 Us Highway 61 Ste 260 Festus MO 63028-4101 Ph: (636) 933-2344 |
| NPI Number | 1023113438 |
|---|---|
| Provider Enumeration Date | 09/13/2006 |
| Last Update Date | 04/26/2021 |
| Medicare PECOS PAC ID | 6608876024 |
|---|---|
| Medicare Enrollment ID | O20070109000582 |
News Archive
Compared to conventional chemotherapy, autologous stem cell transplantation can extend "event-free survival" for breast cancer patients. Clinical trials provide proof of this for breast cancer with and without distant metastases. However, there are indications that this type of stem cell transplantation can more frequently give rise to severe complications affecting almost all organ systems. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 16 December 2009.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.
Lesbian and bisexual older women are more likely than heterosexual older women to suffer chronic health conditions, experience sleep problems and drink excessively, a new University of Washington study finds.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023113438 | NPI | - | NPPES |
| 1578866596 | Other | MO | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MO106962 (Missouri) | Primary |
| Provider Name | Chandra B Dommaraju |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1255361135 PECOS PAC ID: 7315963741 Enrollment ID: I20051017000191 |
News Archive
Compared to conventional chemotherapy, autologous stem cell transplantation can extend "event-free survival" for breast cancer patients. Clinical trials provide proof of this for breast cancer with and without distant metastases. However, there are indications that this type of stem cell transplantation can more frequently give rise to severe complications affecting almost all organ systems. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 16 December 2009.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.
Lesbian and bisexual older women are more likely than heterosexual older women to suffer chronic health conditions, experience sleep problems and drink excessively, a new University of Washington study finds.
› Verified 3 days ago
News Archive
Compared to conventional chemotherapy, autologous stem cell transplantation can extend "event-free survival" for breast cancer patients. Clinical trials provide proof of this for breast cancer with and without distant metastases. However, there are indications that this type of stem cell transplantation can more frequently give rise to severe complications affecting almost all organ systems. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 16 December 2009.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.
Lesbian and bisexual older women are more likely than heterosexual older women to suffer chronic health conditions, experience sleep problems and drink excessively, a new University of Washington study finds.
› Verified 3 days ago
Comtrea Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 112 S 2nd St, Festus, MO 63028 Phone: 636-931-2700 | |
Compass Health, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 222 N Mill St, Festus, MO 63028 Phone: 844-853-8937 | |
Gastroenterology And Liver Consultants Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 420 W Main St, Festus, MO 63028 Phone: 636-931-2320 Fax: 636-937-9693 | |
Southern Missouri Infectious Disease Specialists Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1447 Us Highway 61 Ste C, Festus, MO 63028 Phone: 636-375-4153 Fax: 636-333-4510 | |
Mercy Clinic Adult Hospitalists- Jefferson, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1400 Us Highway 61, Festus, MO 63028 Phone: 314-364-4200 | |
South County Internal Medicine Physicians, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1479 Highway 61, Suite A, Festus, MO 63028 Phone: 636-579-6148 Fax: 888-756-6714 |